Fallout from failed MEI merger continues as Infinity's CEO, CMO exit
Infinity Pharmaceuticals CEO Adelene Perkins and CMO Robert Ilaria were terminated “without cause” from their roles on Sept. 1 as a part of the company’s so-called “August restructuring.” CSO Stéphane Peluso also exited the company.
The Cambridge, MA-based company is still grappling with MEI Pharma scrapping its all-stock merger with Infinity on July 24 due to poor shareholder support. These three exits are designed to save the company money and are on top of its headcount reduction of 21 people — 78% of its employees — right after the failed merger.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
